WHO International Standard
Luteinizing Hormone, Human, Recombinant
NIBSC code: 96/602
Instructions for use
(Version 4.0, Dated 18/01/2008)

1. INTENDED USE
This consists of a batch of ampoules, coded 96/602, containing recombinant luteinizing hormone (rLH) synthesized in Chinese hamster ovary cells (rINN: lutropin alfa). The preparation was examined by international collaborative study and established as the First International Standard for Luteinizing Hormone, Human, Recombinant by the Expert Committee on Biological Standardization of the World Health Organization in November 2003. The main function of 96/602 is to serve as an international standard for the bioassay of therapeutic recombinant LH products.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective clothing and gloves and avoidance of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
Each ampoule of 96/602 contains 189 International Units (IU) per ampoule (by definition).

Uncertainty: the assigned unitage does not carry an uncertainty associated with its calibration. The uncertainty may therefore be considered to be the variance of the ampoule content, and was experimentally determined as ± 0.65% (cv)

4. CONTENTS
Country of origin of biological material: United Kingdom.

Each ampoule contains the residue after freeze-drying of 1.0 ml of a solution that contained:

- Recombinant luteinizing hormone: approx. 8.8µg
- Human plasma albumin: approx. 2mg
- Lactose: approx. 10mg
- Sodium chloride: approx. 8.9mg
- Nitrogen gas at slightly less than atmospheric pressure.

5. STORAGE
Unopened ampoules should be stored at –20°C

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

7. USE OF MATERIAL
For practical purposes each ampoule contains the same quantity of luteinizing hormone. The entire content of each ampoule should be completely dissolved in an accurately measured amount of buffer solution. No attempt should be made to weigh out portions of the freeze dried powder. The use of water to reconstitute ampoule contents is not recommended. The material has not been sterilized and the ampoules contain no bacteriostat.

8. PREPARATION OF AMPOULES
Bulk rLH: This consisted of approximately 118mg of highly purified rLH (Batch no BLBA9410), synthesized in Chinese hamster ovary cells, and generously donated to WHO by Serono, through the good offices of Dr A. Eshkol. It was received as seven 2-ml aliquots of a frozen solution stated to contain 8.42 mg/ml of rLH at a stated specific activity of 17,760 IU/mg, as estimated by the seminal vesicle weight gain bioassay (Van Hettel et al., 1964). Analyses by Serono showed that the identity and purity of this batch of rLH as assessed by SDS-PAGE, isoelectric focusing and size-exclusion HPLC conformed to those of the Serono in-house interim reference preparation.

Distribution into ampoules: LH 96/602 was prepared in September 1996. Some 3.66ml of the bulk solution from two aliquots containing 30.8mg rLH, were diluted to a volume of 3500ml in a solution containing 1%(w/v) lactose, 0.89%(w/v) sodium chloride and 0.2%(w/v) human plasma albumin (Zenalb, batch no ABC 0183, Bio Products Laboratory, Elstree). The solution was distributed into ampoules as approximately 1.0ml aliquots. The solution of rLH was kept at 4°C throughout. The ampoule contents were freeze-dried, secondarily desiccated and sealed under nitrogen (Campbell, 1974; WHO ECBS 1990). The batch consisted of 3401 ampoules. The mean weight of filling solution in 67 weighed ampoules was found to be 1.0072g with a coefficient of variation of 0.65% and a range as % of the mean of 1.01.

9. COLLABORATIVE STUDY
The candidate rLH preparation 96/602 was evaluated by bioassay against current LH reference preparations in an international collaborative study by 9 laboratories in 9 countries using the seminal weight gain bioassay. The LH preparations in the study were also compared by one laboratory in one LH immunoassay system. The objectives of the study were thus:

- to compare by LH bioassay the proposed IS with the fourth International Standard for Human Urinary FSH and LH (IS 98/704) and the second International Standard for Human Pituitary LH (IS 80/552);
- to calibrate the proposed IS by in-vivo LH bioassay in terms of the IS 98/704 and the IS 80/552;
- to estimate the LH bioactivities of accelerated thermal degradation samples of the proposed IS, so as to assess the stability of the proposed IS.

9.1 Activity of ampoule contents
The main function of preparation 96/602 is to serve as an international standard for recombinant LH for bioassay. It was recommended that the value determined relative to the urinary LH standard IS 98/704 be adopted to ensure continuity of the international unit of urinary LH which is currently used to calibrate LH-containing therapeutic products. On this basis, the Expert Committee on Biological Standardization of the World Health Organization established the preparation, in ampoules coded 96/602, as the First International Standard for Luteinizing Hormone, Human, Recombinant and assigned an activity to it of 189 International Units per ampoule.

9.2 Stability
Combining the results of accelerated degradation studies on samples held at elevated temperatures for more than five years gave a predicted yearly loss of activity for samples stored at -20°C of less than 0.01%.
These data indicate that preparation 96/602 is sufficiently stable to serve as an international standard.

10. STABILITY

It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label. For information specific to a particular biological standard, contact standards@nibsc.ac.uk.

In addition, once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use.

NIBSC follows the policy of WHO with respect to its reference materials.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

11. REFERENCES


12. ACKNOWLEDGEMENTS

Grateful acknowledgements are due to the following: the participants in the international collaborative study; Serono (through the good offices of Dr A Eskkol) for providing the bulk rLH; Mr P Gerson, Mrs J Longley, Ms P Lloyd and Mr RJ Tiplady for preliminary bioassays; Dr MP Rose and Dr A Eshkol) for providing the bulk rLH; Mr P Gerson, Mrs J Longley, Ms P Lloyd and Mr RJ Tiplady for preliminary bioassays; Dr MP Rose and Dr P Dawson for ampouling; and to Ms G Creeber for data entry.

13. FURTHER INFORMATION

Further information can be obtained as follows:

This material: enquiries@nibsc.org

WHO Biological Standards:
http://www.who.int/biologicals/en/

JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/

Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx

Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

14. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

15. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

16. MATERIAL SAFETY SHEET


<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th>Physical appearance: Freeze dried powder</th>
<th>Corrosive:</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable:</td>
<td>Oxidising:</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Hygroscopic:</td>
<td>Implant:</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Flammable:</td>
<td>Handling:</td>
<td>See caution, Section 2</td>
<td></td>
</tr>
<tr>
<td>Other (specify):</td>
<td>Contains material of human origin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Toxicological properties**

| Effects of inhalation: | Not established, avoid inhalation |
| Effects of ingestion:  | Not established, avoid ingestion |
| Effects of skin absorption: | Not established, avoid contact with skin |

**Suggested First Aid**

Inhalation: Seek medical advice

Ingestion: Seek medical advice

Contact with eyes: Wash with copious amounts of water. Seek medical advice

Contact with skin: Wash thoroughly with water.

**Action on Spillage and Method of Disposal**

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

17. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

18. INFORMATION FOR CUSTOMS USE ONLY

| Country of origin for customs purposes*: United Kingdom |
| Net weight: | 21mg |
| Toxicity Statement: | Non-toxic |
| Veterinary certificate or other statement if applicable. | Attached: No |

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
17. CERTIFICATE OF ANALYSIS
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.